The domestic pharmaceutical R&D expenditure is expected to reach 49.6 billion US dollars in 2025, and the innovation environment will usher in a huge change

In recent years, China has successively issued a series of policy documents, such as drug registration classification, drug marketing authorization holder system, priority review and approval, and resolution of drug registration application backlogs, etc.
, which have better promoted the improvement of the efficiency of innovative drug research and development, and pharmaceutical innovation The overall environment has been greatly optimized
.
Under the optimization of the policy environment, pharmaceutical companies are enthusiastic about innovation and R&D
.
Data show that China’s pharmaceutical R&D investment in 2014 was 9.
3 billion U.
S.
dollars and increased to 17.
4 billion U.
S.
dollars in 2018.
By 2020, China’s pharmaceutical R&D investment will be 24.
7 billion U.
S.
dollars, accounting for 12.
1% of global drug R&D expenditures
.
According to statistics, in 2025, China's expenditure on drug research and development may reach 49.
6 billion U.
S.
dollars, with an average annual compound growth rate of about 15%, or twice the global level over the same period
.
The rapid development of the pharmaceutical market has brought huge opportunities and challenges to the industry.
Nowadays, many companies have poured in and continue to promote drug innovation and research and development
.
According to the industry, with the rising enthusiasm of pharmaceutical companies for innovation and R&D, the pharmaceutical market may usher in a new look
.
Recently, China Health Think Tank and Head Leopard Research Institute jointly released the "2021 China Pharmaceutical Product Innovation Briefing".
The recommended Chinese pharmaceutical product innovation companies shown in the report include Yuekang Pharmaceutical, Kangzhe Pharmaceutical, Sansheng Pharmaceutical, Tengsheng Bo Yao, Hengrui Pharmaceutical, Weiguang Bio, Huaxi Biological, BeiGene, Jiangsu Haosen, Kangtai Biological, Fosun Pharmaceutical, Watson Biological, Shanghai Hongbo Zhiyuan Pharmaceutical, Guobang Pharmaceutical, Heyuan Biological, Yongtai Biological, Green Gu Pharmaceutical, Health Yuan
.
Among them, Yuekang Pharmaceutical was established in 2001.
In the past two decades, Yuekang Pharmaceutical’s R&D base in Beijing has three major business departments: scientific research department, registration department, and clinical research department.
Among them, 39 projects are under research, including antibiotics, stomach Intestinal, anti-tumor, immunomodulatory, hypoglycemic, cardiovascular and cerebrovascular, anti-hepatitis B, antiviral, antibacterial and other therapeutic fields
.
The company’s main business covers the entire industry chain of drug research and development, manufacturing, circulation and sales, with a variety of dosage forms such as injections, freeze-dried powder injections, tablets, capsules, and the production capacity of some APIs; products cover cardiovascular, cerebrovascular, and digestive systems , Anti-infection, endocrine and anti-tumor drugs in 12 fields
.
As a large-scale pharmaceutical enterprise group dominated by high-end chemical drugs, Yuekang Pharmaceutical insists on R&D innovation as the driving force, and is committed to building an enterprise integrating the R&D, production and sales of chemical raw materials, high-end chemical drugs and biological drugs
.
Relying on the brand advantages accumulated over the years, Yuekang Pharmaceutical has cooperated with domestic and foreign universities, scientific research institutes, etc.
, and has established a full-process drug R&D control system covering generic drugs and innovative drugs from project approval to post-marketing
.
Established in 2006, CMS is a global innovation-driven professional pharmaceutical company focusing on the Chinese market
.
In the development of CMS, the innovation pipeline continues to advance and expand.
The company's diazepam nasal spray is expected to be approved for marketing this year; 0.
09% cyclosporine eye drops, tilapizumab (IL-23), and doxorubicin hydrochloride Star liposomes are expected to be approved for listing in 2022; Dedurestat (CKD anemia), methotrexate prefillers, and methylene blue MMX are expected to be approved for listing in 2023, adding new impetus to the company's long-term growth rate
.
It is understood that the company currently obtains licenses for 5 innovative drugs each year, including plans to launch epilepsy sprays in China this year.
It is expected to continue to contribute to revenue.
The target price has been raised from 11.
1 Hong Kong dollars to 26 Hong Kong dollars
.
In terms of R&D, 3SBio continues to accelerate the pipeline advancement speed through independent R&D and external cooperation
.
Data show that in the first half of 2021, 3SBio's R&D investment increased by 36% year-on-year to 340 million yuan, and the advancement of the pipeline in research has increased
.
In the first half of the year, 3SBio's treatment areas covered 14 oncology, 14 autoimmune and other diseases, 6 nephrology, and 1 dermatology.
It has a total of 35 products under development, of which 24 are innovative drug developments
.
In the development of innovative drugs, Hengrui Medicine has basically formed a benign development trend in which innovative drugs are applied for clinical applications every year, and innovative drugs are listed every 1-2 years
.
Among them, innovative drugs are irecoxib, apatinib mesylate, thiopefigrastim, pyrrotinib maleate, carrelizumab, remazolam tosylate and fluzoparib Approved for listing
.
In the third quarter of this year, Hengrui Pharmaceutical's innovative drugs accounted for nearly 40% of the overall revenue.
Many innovative drugs have been completed in different stages of research and development.
In the next 2-3 years, the company will have as many as 15 innovative drugs approved for listing, which is hopeful to make up for imitations.
Pharmaceutical decline
.
BeiGene once again boarded the "C-level stage" of China's innovative drug market, that is, on the evening of November 16, the China Securities Regulatory Commission issued an announcement agreeing that BeiGene will raise funds for the first time on the science and technology board, and it may become a US company.
Biomedical companies listed on Nasdaq, Hong Kong, China and Shanghai Science and Technology Innovation Board
.
Data show that since 2013, BeiGene's R&D investment has continued to grow
.
In 2020 alone, R&D expenses will be nearly 1.
3 billion U.
S.
dollars (approximately RMB 8.
45 billion).
.
.
After years of hard work, China's biopharmaceutical industry has undergone significant changes, from the past generic drug-based pharmaceutical industry to innovative research and development.
, Even self-study
.
As the reform of the drug review system kicked off in 2015, favorable policies for innovative drugs were continuously introduced, and the demand for China's biomedicine market continued to expand, which also attracted the influx of domestic and foreign capital and the return of a large number of global scientists and overseas returnees
.
Nowadays, the number of patents for innovative drugs in China occupies a large position in the world, surpassing traditional pharmaceutical powers such as Japan, the United Kingdom, and Germany in the second echelon, and the innovation ecology has begun to take shape
.